Literature DB >> 22653076

Use of a surgical specimen-collection kit to improve mediastinal lymph-node examination of resectable lung cancer.

Raymond U Osarogiagbon1, Laura E Miller, Robert A Ramirez, Christopher G Wang, Thomas F O'Brien, Xinhua Yu, Alim Khandekar, Glenn P Schoettle, Samuel G Robbins, Edward T Robbins, Jeffrey B Gibson.   

Abstract

INTRODUCTION: Pathologic examination of mediastinal lymph nodes (MLNs) after resection of non-small-cell lung cancer is critical in the determination of prognosis and postoperative management. Although systematic nodal dissection is recommended, the quality of pathologic lymph-node staging often falls short of recommendations in practice. We tested the feasibility of improving pathologic lymph-node staging of resectable non-small-cell lung cancer by using a prelabeled specimen-collection kit.
METHODS: Case-control study with comparison of 51 resections, using a special lymph-node collection kit, with 51 controls matched for surgeon, extent of resection, pathologist, and T category. Appropriate statistical methods were used for all comparisons.
RESULTS: The median number of MLNs examined increased from one in the control group, to six in the case group (p < 0.001). The percentage of resections attaining the National Comprehensive Cancer Network-recommended quality of MLN examination, and the proportion that would have been eligible for recent landmark postresection adjuvant therapy trials increased significantly (p < 0.001). The duration of surgery and postoperative complication rates were similar between cases and controls. Eighteen percent of kit cases had positive MLN, compared with 8% of controls.
CONCLUSIONS: The use of a specialized specimen-collection kit for MLN examination was feasible, markedly improved MLN staging, and showed a trend toward increased detection of patients with MLN metastasis, with only a modest increase in duration of surgery, and no increase in perioperative morbidity, mortality, or hospital length of stay.

Entities:  

Mesh:

Year:  2012        PMID: 22653076     DOI: 10.1097/JTO.0b013e318257fbe5

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  17 in total

1.  Response to: intrapulmonary lymph node retrieval.

Authors:  Christina Brzezniak; Giuseppe Giaccone
Journal:  Transl Lung Cancer Res       Date:  2013-04

2.  Response to editorial titled 'Intrapulmonary lymph node retrieval: unclear benefit for aggressive pathologic dissection'.

Authors:  Raymond U Osarogiagbon; Laura E Miller; Christopher G Wang; Robert A Ramirez
Journal:  Transl Lung Cancer Res       Date:  2013-04

Review 3.  Towards optimal pathologic staging of resectable non-small cell lung cancer.

Authors:  Raymond U Osarogiagbon; Gail E Darling
Journal:  Transl Lung Cancer Res       Date:  2013-10

4.  The impact of a novel lung gross dissection protocol on intrapulmonary lymph node retrieval from lung cancer resection specimens.

Authors:  Raymond U Osarogiagbon; Ransome Eke; Srishti Sareen; Cynthia Leary; LaShundra Coleman; Nicholas Faris; Xinhua Yu; David Spencer
Journal:  Ann Diagn Pathol       Date:  2014-04-26       Impact factor: 2.090

5.  Prognostic Value of National Comprehensive Cancer Network Lung Cancer Resection Quality Criteria.

Authors:  Raymond U Osarogiagbon; Meredith A Ray; Nicholas R Faris; Matthew P Smeltzer; Carrie Fehnel; Cheryl Houston-Harris; Raymond S Signore; Laura M McHugh; Paul Levy; Lynn Wiggins; Vishal Sachdev; Edward T Robbins
Journal:  Ann Thorac Surg       Date:  2017-03-31       Impact factor: 4.330

6.  Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer.

Authors:  Meredith A Ray; Nicholas R Faris; Matthew P Smeltzer; Carrie Fehnel; Cheryl Houston-Harris; Paul Levy; Lynn Wiggins; Vishal Sachdev; Todd Robbins; David Spencer; Raymond U Osarogiagbon
Journal:  Ann Thorac Surg       Date:  2018-03-11       Impact factor: 4.330

7.  Audit of lymphadenectomy in lung cancer resections using a specimen collection kit and checklist.

Authors:  Raymond U Osarogiagbon; Srishti Sareen; Ransome Eke; Xinhua Yu; Laura M McHugh; Kemp H Kernstine; Joe B Putnam; Edward T Robbins
Journal:  Ann Thorac Surg       Date:  2014-12-19       Impact factor: 4.330

Review 8.  Measuring improvement in populations: implementing and evaluating successful change in lung cancer care.

Authors:  Xinhua Yu; Lisa M Klesges; Mathew P Smeltzer; Raymond U Osarogiagbon
Journal:  Transl Lung Cancer Res       Date:  2015-08

9.  Improving the pathologic evaluation of lung cancer resection specimens.

Authors:  Raymond U Osarogiagbon; Holly L Hilsenbeck; Elizabeth W Sales; Allen Berry; Robert W Jarrett; Christopher S Giampapa; Clara N Finch-Cruz; David Spencer
Journal:  Transl Lung Cancer Res       Date:  2015-08

10.  Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival.

Authors:  Pamela Samson; Traves Crabtree; Stephen Broderick; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2016-09-21       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.